Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET
Company Participants
Jenny Kobin - Investor Relations
George Lasezkay - President and Chief Executive Officer
Charles Deignan - Chief Financial Officer
Conference Call Participants
Annabel Samimy - Stifel
Serge Belanger - Needham & Company
Jonathan Wolleben - JMP Securities
Yi Chen - H.C. Wainwright
Operator
Good day and thank you for standing by and welcome to the Clearside Biomedical Fourth Quarter 2022 Financial Results and Corporate Update Conference Call. At this time all participants are in a listen-only mode. After the speakers' presentation there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Jenny Kobin, Investor Relations. Please go ahead.
Jenny Kobin
Good afternoon everyone and thank you for joining us on the call today. Before we begin, I would like to remind you that during today's call, we will be making certain forward-looking statements. Various remarks that we make during this call about the company's future expectations, plans and prospects constitute forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2021, our quarterly report on Form 10-Q for the quarter ended September 30, 2022 and our other SEC filings available on our website. We expect that our 10-K for the year ended December 31, 2022 will be filed tomorrow.
In addition, any forward-looking statements represent our views as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so even if our views change.
On today's call we have George Lasezkay, our Chief Executive Officer and Charles Deignan, our Chief Financial Officer. After formal remarks, we will open the call for your questions.
I would now like to turn the call over to George.
George Lasezkay
Thank you, Jenny. Over the past year, we have reinforced Clearside's leadership position in the delivery of therapeutics into the Suprachoroidal Space. We've successfully executed on our strategic plans with the launch and commercialization of the first FDA approved suprachoroidal product, XIPERE by our partner Bausch + Lomb and we completed and announced positive data from our Phase 1/2a OASIS trial of CLS-AX in Wet AMD. We have also seen promising data presented by partners utilizing our proprietary SCS Microinjector to administer gene therapy and oncology agents to treat a variety of diseases.